Intetumumab
Intetumumab
Intetumumab (pronunciation: in-teh-too-moo-mab) is a type of monoclonal antibody that is being studied in the treatment of certain types of cancer. It is a type of angiogenesis inhibitor and a type of VEGF inhibitor.
Etymology
The name "Intetumumab" is derived from the International Nonproprietary Names (INN), where "int" refers to interference, "etu" refers to human, "mu" refers to mus, and "mab" is indicative of its status as a monoclonal antibody.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Angiogenesis inhibitor: A substance that inhibits the growth of new blood vessels (angiogenesis). In cancer treatment, angiogenesis inhibitors may prevent the growth of new blood vessels that tumors need to grow.
- VEGF inhibitor: A type of drug that blocks vascular endothelial growth factor (VEGF), which may prevent the growth of new blood vessels that tumors need to grow.
- Cancer: A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Cancer cells can also spread to other parts of the body through the blood and lymph systems.
External links
- Medical encyclopedia article on Intetumumab
- Wikipedia's article - Intetumumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski